Pharma companies directory 2026

    Pharmaceutical Companies in Tunisia

    Tunisia is the rare Maghreb market where a state wholesaler still holds a legal monopoly on importing finished medicines, so a foreign brand’s first counterpart is the Pharmacie Centrale de Tunisie rather than a private agent.

    About forty human-medicine plants, according to the national industry chamber in early 2026, already cover most volume and a smaller share of value; SIPHAT, Unimed, Adwya, Teriak, SAIPH and Médis sell generics at home and ship sterile and solid forms into African and some European channels. CNAM reimbursement, not detailing alone, decides whether an originator will ever leave the private cash niche. ANMPS, the agency that absorbed the old Direction de la Pharmacie et du Médicament, now takes eCTD files. Registration, PCT listing, a CNAM code and only then pharmacy demand is the sequence a launch team has to respect.

    Updated September 2026 · Ministère de la Santé / ANMPS (successor to the Direction de la Pharmacie et du Médicament) — medicine regulation as of September 2026 · 18 named accounts

    Request a proposal for TunisiaBrowse the 18 companies

    40

    Human-medicine plants cited by the Chambre Nationale de l’Industrie Pharmaceutique, February 2026

    ~80% / ~60%

    Local share of needs by volume versus by value, same CNIP statement

    TND 250–300m

    Annual pharmaceutical export earnings cited in 2026 investment-promotion briefings

    PCT

    Legal monopoly holder for finished-medicine imports

    Named accounts

    Top pharmaceutical companies in Tunisia

    Public, well-known names BioNixus studies at account and SKU level. This is an editorial snapshot, not an endorsement or a market-share ranking. Cross-checked against Ministère de la Santé / ANMPS (successor to the Direction de la Pharmacie et du Médicament) — medicine regulation (as of 2026-09-04).
    #CompanyHQ
    01SIPHATTunis
    02UnimedSousse
    03AdwyaTunis
    04TeriakTunis
    05Opalia RecordatiTunis
    06SAIPHTunis
    07Laboratoires MédisNabeul
    08GalpharmaSfax
    09Taha PharmaTunis
    10Sanofi TunisiaTunis
    11Hikma TunisiaTunis
    12Pfizer TunisiaTunis
    13Novartis TunisiaTunis
    14Roche TunisiaTunis
    15Pierre Fabre TunisieTunis
    16Pharmacie Centrale de Tunisie (PCT)Tunis
    17CNAM (Caisse Nationale d’Assurance Maladie)Tunis
    18ANMPS (Agence Nationale du Médicament et des Produits de Santé)Tunis

    Primary research

    These are the pharmaceutical companies accounts we study in Tunisia

    Need account-level or SKU-level data for a brand in Tunisia? BioNixus runs primary fieldwork — brand vs competitors, including the channels a dashboard averages away. Proposal ready within 48 hours of a brief.

    Planning research in Tunisia?

    Primary research, market access & HEOR. Proposals within 48 hours.

    Top market research companies in Tunisia (2026)

    How the market is structured

    PCT as the gate for every imported pack

    Finished imports cannot legally bypass the Pharmacie Centrale de Tunisie. PCT buys in hard currency, sells on in dinars, supplies public hospitals from its own warehouses, and also feeds the private wholesale layer that reaches community pharmacies; local factories, by contrast, may sell their own manufacture into the private channel without sitting inside that import monopoly. Price is set with the health and trade ministries before a marketing authorisation is usable, and a CNAM listing is a separate later fight — without it, an originator stays a cash product for the minority of patients who will pay. ANMPS inherited the DPM’s registration, inspection and clinical-trial files and spent 2025 putting eCTD and a digital portal in front of applicants, so timelines now depend on both the old committee culture and the new software. Export is the safety valve: Unimed’s sterile lines, Teriak’s Kilani-group plants, SAIPH’s West African bets and Adwya’s Côte d’Ivoire promotion office exist because the domestic price-and-arrears system cannot absorb all the capacity those factories built. Sfax and Tunis remain the two detailing poles; hospital demand is a PCT tender conversation, not a ward-by-ward sale.

    Local

    Tunisian factories — public SIPHAT and a private bench led by Unimed, Adwya and Teriak — that already hold most volume at home and treat African and European export as the way out of PCT price-and-arrears gravity.

    • SIPHAT
    • Unimed
    • Adwya
    • Teriak
    • SAIPH
    • Laboratoires Médis
    • Galpharma
    • Taha Pharma

    Multinational

    European affiliates that accept a PCT monopoly and a CNAM listing fight as the price of staying, with Opalia Recordati the one that also manufactures on Tunisian soil.

    • Opalia Recordati
    • Sanofi Tunisia
    • Pfizer Tunisia
    • Novartis Tunisia
    • Roche Tunisia
    • Pierre Fabre Tunisie

    Regional

    Hikma and other Levant or Maghreb groups that use Tunis as a commercial node and sometimes as a supply source for neighbouring tenders.

    • Hikma Tunisia

    Distributors & importers

    PCT as importer and hospital supplier, CNAM as the reimbursement gate, and ANMPS as the successor regulator that now wants dossiers in eCTD.

    • Pharmacie Centrale de Tunisie (PCT)
    • CNAM (Caisse Nationale d’Assurance Maladie)
    • ANMPS (Agence Nationale du Médicament et des Produits de Santé)

    What is moving

    What is moving the pharmaceutical market in Tunisia

    PCT arrears and the dinar-price straitjacket

    Because PCT buys in euros or dollars and sells in dinars, every devaluation lands on its balance sheet; affiliates then face delayed payment and pressure to cut prices, which is why several have thinned their Tunisian lists.

    CNAM listing as the real launch

    A registration that never receives a reimbursement code stays a cash niche. Originators therefore budget as much time for CNAM as for ANMPS, and generic houses live on the codes they already hold.

    Sterile and generic export into Africa and Europe

    Unimed, Teriak, SAIPH and Adwya built extra capacity for buyers outside Tunisia; chamber and FIPA briefings in 2026 still put annual export earnings in the mid-hundreds of millions of dinars.

    ANMPS digital files

    eCTD and the 2025 portal will not make Tunisia a fast agency overnight, but they change how foreign regulatory groups prepare a Maghreb submission and who inside ANMPS owns the clock.

    BioNixus fieldwork

    How BioNixus studies pharmaceutical companies in Tunisia

    The accounts above are the ones our field teams and analysts work with. What a brand team typically commissions from us in Tunisia:
    • Tunis Bab Saadoun and Sfax pharmacy purchase logs that split each molecule into PCT-imported originator, local generic and unpaid-or-missing SKU, then match the split to CNAM codes.
    • Structured interviews with PCT buyers and hospital pharmacists on arrears, substitution when an originator is delayed, and which Tunisian sterile houses win hospital volume.
    • CNAM listing post-mortems with affiliate access managers: dossier clocks, unpublished refusal reasons, and the cash-only life of a brand that never received a code.
    • Export-file reviews with Unimed and Teriak regulatory staff covering African and European registrations, used when a client wants Tunisia as a supply base rather than only as a sales market.

    Questions

    Frequently Asked Questions

    Can a foreign company appoint a private importer in Tunisia?

    Not for finished medicines. PCT holds the legal monopoly on import. A private wholesaler may distribute after PCT has landed the goods, and a local factory may sell what it manufactures itself, but the import door is public.

    How much of Tunisia’s medicine use is made at home?

    The industry chamber’s February 2026 figures were about four fifths of volume and about three fifths of value, from forty human-medicine plants. Value lags volume because originators and complex imports still dominate the expensive SKUs.

    Why do Tunisian manufacturers talk so much about export?

    Domestic prices are administered, PCT and CNAM pay late, and the factories have more capacity than the home market will reward. West Africa, the Maghreb and selected European buyers are how Unimed, SAIPH and Teriak keep lines busy.

    What happened to the Direction de la Pharmacie et du Médicament?

    Law 2023-2 created ANMPS under the Ministry of Health and moved registration, inspection and trial authorisation onto the new agency. Older DPM pages and habits still appear in correspondence, but the legal counterpart for a 2026 file is ANMPS.

    What does a BioNixus Tunisia pharmaceutical study actually field?

    PCT circular and tender reconstruction; CNAM listing interviews in Tunis; pharmacy purchase checks in Tunis and Sfax that separate local generics from PCT-imported originators; and export-registration mapping for sterile houses.

    Does the order of Tunisian names in this table mean anything about size?

    Names sit here because they sit on PCT circulars, BVMT filings or ANMPS correspondence, not because a turnover table put them in this sequence. The page is an account guide.

    Sources

    Data sources & methodology

    This directory aggregates publicly available company and channel facts — filings, brand sites, and BioNixus fieldwork in Tunisia. It is an editorial snapshot of the accounts we study, not a share ranking and not a substitute for NielsenIQ, IQVIA, or another syndicated feed.

    Primary register: Ministère de la Santé / ANMPS (successor to the Direction de la Pharmacie et du Médicament) — medicine regulation, consulted 2026-09-04. Company classification (Local / MNC / Regional / distributors & importers) reflects ownership and role in Tunisia, not size.

    • Chambre Nationale de l’Industrie Pharmaceutique remarks on plant count and local volume/value coverage, La Presse de Tunisie, February 2026
    • FIPA-Tunisia / investment-promotion briefings on export earnings, February 2026; TIA pharmaceutical value-chain notes on Adwya, Unimed, Teriak and SAIPH
    • Law 2023-2 creating ANMPS; La Presse reporting on the January 2025 digital and eCTD launch
    • Pharmacie Centrale de Tunisie institutional site (phct.com.tn) on import monopoly and hospital supply
    • BioNixus Tunisia PCT, CNAM and pharmacy fieldwork, 2023–2026

    BioNixus sells account-level and SKU-level primary research that complements those subscriptions. For a scoped proposal, contact the team or use the form below. Email admin@bionixus.com.

    48-hour proposal

    Need brand and competitor data in Tunisia?

    Physician, pharmacist and payer fieldwork on the accounts above — prescription share, formulary position and tender exposure. Proposal within 48 hours.

    Planning research in Tunisia?

    Primary research, market access & HEOR. Proposals within 48 hours.